COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: “what the bleep do we know?”
Abstract The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a “Pandemic” and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strat...
Main Authors: | Salman Mansoor, Siobhan Kelly, Kevin Murphy, Aine Waters, Nauman Saleem Siddiqui |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2020-05-01
|
Series: | The Egyptian Journal of Neurology, Psychiatry and Neurosurgery |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s41983-020-00177-0 |
Similar Items
-
Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know
by: Marina Kleopatra Boziki, et al.
Published: (2020-04-01) -
REVIEW ON MULTIPLE SCLEROSIS MANAGEMENT IN TIMES OF SARS-COV-2 PANDEMIC
by: Georgiana SERBAN, et al.
Published: (2020-06-01) -
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
by: Serena Brancati, et al.
Published: (2021-07-01) -
Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): “a case report from Ireland with review of literature, clinical pitfalls and future direction”
by: Salman Mansoor, et al.
Published: (2021-01-01) -
Management of Patients with Multiple Sclerosis During the COVID-19 Pandemics: A Portuguese Single-Centre Experience
by: Miguel Miranda, et al.
Published: (2021-02-01)